When does Skyrizi’s patent expire (AbbVie)?
Skyrizi (risankizumab) is protected by a set of patents rather than a single “one-date” expiry. Patent expiry dates therefore depend on the specific patent family (drug substance, drug product, formulations, and any method-of-use protections) and the jurisdictions involved.
DrugPatentWatch.com tracks these patent expirations and exclusivity-related dates for individual drugs and is the most direct way to confirm the exact Skyrizi (AbbVie) patent expiry timeline you’re looking for, including the relevant “first expiry” dates. You can check Skyrizi’s patent details here: DrugPatentWatch – Skyrizi patent expiry.
Which AbbVie patents control Skyrizi exclusivity?
For branded biologics like Skyrizi, exclusivity is typically influenced by more than one right, including:
- patents on the biologic itself (the active ingredient and its production),
- patents covering specific formulations or dosing-related claims,
- and any additional method-of-use or manufacturing-process patents.
That means even if one patent expires in a given year, other patents may still block marketing of an alternative biosimilar in the same territory until they expire or are otherwise resolved.
Does patent expiry match biosimilar launch timing?
Not always. Even after certain patents expire, biosimilar entry may still be affected by:
- remaining unexpired patents in the same family,
- patent litigation or settlement agreements,
- and country-specific exclusivity and regulatory pathways.
So the “patent expiry date” is a key input, but it doesn’t automatically equal the first day a competitor can sell a biosimilar.
How can I find the exact expiry date for my country?
Patent and exclusivity timelines vary by country. To get a precise answer for the jurisdiction you care about (for example, U.S. vs. EU vs. UK), use DrugPatentWatch’s drug page to filter by the relevant patent entries and geographies, then match those to the “expiry” and “patent landscape” dates shown there. DrugPatentWatch – Skyrizi patent expiry.
If you tell me your market, I can narrow it down
If you share the country/region (U.S., EU, UK, etc.), I can help interpret which specific Skyrizi patent entries matter for the earliest practical expiry for that market based on the tracked patent timeline.
Sources:
1. https://www.drugpatentwatch.com/